Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | MAP2K1 |
Variant | P124Q |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | MAP2K1 P124Q lies within the protein kinase domain of the Map2k1 protein (UniProt.org). P124Q results in increased Erk1/2 phosphorylation in culture, and is associated with decreased sensitivity to Raf inhibition (PMID: 25370473), but demonstrates autophosphorylation and kinase activity similar to wild-type Map2k1 in another study (PMID: 29753091), and therefore, its effect on Map2k1 protein function is unknown. |
Associated Drug Resistance | |
Category Variants Paths |
MAP2K1 mutant MAP2K1 P124Q |
Transcript | NM_002755.4 |
gDNA | chr15:g.66436825C>A |
cDNA | c.371C>A |
Protein | p.P124Q |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_017022411.3 | chr15:g.66436825C>A | c.371C>A | p.P124Q | RefSeq | GRCh38/hg38 |
XM_017022411.2 | chr15:g.66436825C>A | c.371C>A | p.P124Q | RefSeq | GRCh38/hg38 |
NM_002755.3 | chr15:g.66436825C>A | c.371C>A | p.P124Q | RefSeq | GRCh38/hg38 |
NM_002755 | chr15:g.66436825C>A | c.371C>A | p.P124Q | RefSeq | GRCh38/hg38 |
XM_017022411 | chr15:g.66436825C>A | c.371C>A | p.P124Q | RefSeq | GRCh38/hg38 |
NM_002755.4 | chr15:g.66436825C>A | c.371C>A | p.P124Q | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MAP2K1 P124Q | lymphatic system cancer | predicted - sensitive | Cobimetinib | Case Reports/Case Series | Actionable | In a Phase II trial, treatment with Cotellic (cobimetinib) in patients with histiocytic neoplasms resulted in a PET overall response rate of 89% (16/18), with complete response in 72% (13/18) and partial response in 17% (3/18), and resulted in stable disease in 6% (1/18) of patients, including a complete response in a patient with Erdheim-Chester disease harboring MAP2K1 P124Q (PMID: 30867592; NCT01953926). | 30867592 |